Malaria (Plasmodium): A-Level Biology Revision Notes
Malaria is one of the world’s most significant and ancient infectious diseases, primarily afflicting tropical and subtropical regions. It is classified as a vector-borne disease and remains a leading cause of morbidity and mortality, especially among young children in sub-Saharan Africa. For A-Level Biology, understanding the causative agent, the complex life cycle, transmission, and control measures is essential.
Causative Agent and Species
The disease is caused by protozoan parasites belonging to the genus Plasmodium, which are single-celled, obligate parasites. Although over 150 species of Plasmodium exist, only five are commonly known to infect humans: Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi.
Of these, Plasmodium falciparum is the most virulent and accounts for the vast majority of severe illness and malaria-related deaths worldwide. It is particularly dominant in the African continent and is associated with the highest levels of parasitaemia (parasite burden in the blood). Plasmodium vivax is the most prevalent species outside of Africa and is known for its ability to cause relapses months or years after the initial infection due to dormant liver stages called hypnozoites (a feature also seen in P. ovale). The severity of the disease and the resulting complications are directly linked to the species of Plasmodium involved and its rate of reproduction within the host’s red blood cells (RBCs).
Transmission and the Vector
Malaria is primarily transmitted through the bite of an infected female Anopheles mosquito, which acts as the biological vector. Only the female mosquito feeds on blood, as it requires the protein for egg development. During a blood meal on an infected human, the mosquito ingests the parasite’s sexual forms (gametocytes). The parasite develops and replicates within the mosquito over approximately two weeks before being transferred back to a healthy human when the infected mosquito bites again.
While the vector-borne route is the most common, malaria can also be transmitted via direct exposure to infected blood. This happens through blood transfusions, organ transplantation, sharing contaminated needles (particularly among drug users), or vertically from mother to foetus across the placenta (congenital malaria). Malaria is endemic in areas with high temperatures and rainfall, which provide the hot and humid climate necessary for the Anopheles mosquito to thrive and complete the parasite’s life cycle effectively.
The Complex Life Cycle: The Human Host (Asexual Stages)
The life cycle is complex, involving two hosts and three main replication cycles: the sporogonic cycle (in the mosquito), the exo-erythrocytic cycle (in the human liver), and the erythrocytic cycle (in human red blood cells or RBCs).
1. Exo-erythrocytic (Liver) Cycle: When an infected mosquito bites a human, it inoculates the infective stage, known as sporozoites, into the bloodstream. These motile sporozoites rapidly travel to the liver and invade liver cells (hepatocytes) within 30-60 minutes. Inside the hepatocytes, they undergo a rapid asexual replication process called schizogony to form thousands of merozoites. This liver stage, which typically lasts 7–10 days, is asymptomatic. The infected liver cells rupture, releasing the merozoites into the bloodstream. In P. vivax and P. ovale, some parasites enter a dormant liver stage called hypnozoites, which can reactivate later to cause clinical relapse, making treatment more challenging.
2. Erythrocytic (Blood) Cycle: This is the symptomatic stage. Once released from the liver, merozoites quickly invade new red blood cells. They attach to specific receptors on the RBC surface (e.g., Glycophorin A) and actively invade the cell. Inside the RBCs, they differentiate into the ring stage (early trophozoite), mature into a trophozoite (feeding stage), and then undergo further asexual replication to form schizonts. The schizonts then lyse (rupture) the RBC, releasing numerous new merozoites (typically 8–32) to invade other healthy RBCs. This cycle repeats approximately every 48 to 72 hours, leading to a geometric increase in the parasite population (parasitaemia) and the characteristic cyclical fevers of malaria.
The Complex Life Cycle: The Mosquito Host (Sexual Stages)
After several rounds of asexual replication in the blood, a small portion of merozoites differentiate into the sexual forms of the parasite, the male microgametocytes and female macrogametocytes. These gametocytes circulate in the peripheral blood but are non-replicating in the human. They are the essential stage for transmission back to the mosquito vector.
When a female Anopheles mosquito takes a blood meal from an infected person, it ingests these gametocytes. Inside the mosquito’s midgut, the gametocytes undergo sexual reproduction (sporogonic cycle). The male and female gametes are formed (exflagellation), and the microgamete (male) fertilises the macrogamete (female) to form a diploid zygote. The zygote transforms into a motile and elongated ookinete. The ookinete penetrates the mosquito’s gut wall and develops into an oocyst on the external surface of the midgut. Within the oocyst, thousands of new sporozoites are produced through meiotic and mitotic divisions. When the oocyst ruptures, the sporozoites migrate to the mosquito’s salivary glands, making the mosquito infectious and ready to perpetuate the cycle upon biting a new human host.
Symptoms and Pathogenesis
The clinical symptoms of malaria are entirely due to the erythrocytic cycle (blood stage), beginning with the rupture of red blood cells and the release of merozoites, parasite waste products, and inflammatory mediators into the bloodstream. The typical incubation period is 10-18 days.
The hallmark clinical features of uncomplicated malaria are:
– **Cyclical Fevers and Chills:** The periodic rupture of RBCs is thought to trigger the release of pyrogens, leading to episodes of shivering, chills (rigors), high fever (up to 41°C), and drenching sweats, which are characteristic of malaria. These episodes often become synchronous, correlating with the species’ asexual replication cycle.
– **Fatigue and Anemia:** The massive destruction of RBCs (hemolysis) causes hemolytic anaemia, which leads to extreme fatigue, weakness, and paleness. Reduced production of new red blood cells during infection further exacerbates the anemia.
– **Other Common Symptoms:** Headache, nausea, vomiting, joint and muscle pain, and general malaise.
The deadliest complication is Severe Malaria, almost exclusively caused by P. falciparum. A key factor in its pathogenesis is the ability of P. falciparum to modify the surface of the infected RBCs, making them ‘sticky’ (cytoadherence). These infected cells then sequester (adhere) to the endothelial lining of small blood vessels (capillaries) in major organs, particularly the brain, lungs, and kidneys. This sequestration blocks blood flow and oxygen supply, leading to severe organ damage and life-threatening conditions such as Cerebral Malaria (impaired consciousness, seizures, coma), Acute Respiratory Distress Syndrome (ARDS), and kidney failure. Severe malaria can be fatal within 24 hours if untreated. Specific acquired immunity against severe malaria develops over time due to repeated infections, which is why severe malaria is predominantly a disease of young children in endemic areas.
Diagnosis, Treatment, and Prevention
Early diagnosis and prompt treatment are crucial for preventing death and reducing transmission.
Diagnosis: The gold standard diagnostic method is the microscopic examination of a Giemsa-stained thick and thin blood film. The thick film concentrates the cells, allowing for the detection of the parasite and quantification of parasitaemia (parasite burden). The thin film is used to identify the specific Plasmodium species. Rapid Diagnostic Tests (RDTs) are also commonly used, especially in remote areas, as they quickly detect malarial antigens (e.g., histidine-rich protein 2 or Plasmodium lactate dehydrogenase) in the blood.
Treatment: Treatment relies heavily on antimalarial drugs. The WHO recommends Artemisinin-based Combination Therapies (ACTs) for uncomplicated P. falciparum malaria due to their high efficacy and ability to overcome drug resistance. For severe malaria, immediate intravenous administration of artemisinin derivatives (e.g., artesunate) is required. Radical cure for P. vivax and P. ovale also requires treatment for the dormant hypnozoites (e.g., with primaquine or tafenoquine), which necessitates a preliminary test for the patient’s glucose-6-phosphate-dehydrogenase (G6PD) status to prevent severe hemolysis.
Prevention and Control: Control strategies focus on both mosquito management and personal protection:
– **Vector Control:** Core strategies include the use of Insecticide-Treated Nets (ITNs) for sleeping and Indoor Residual Spraying (IRS) of household walls with residual insecticides to kill resting mosquitoes. These methods are highly effective in reducing transmission.
– **Personal Protection:** Wearing protective clothing, using topical insect repellents (containing DEET or Icaridin), and chemoprophylaxis (taking preventive antimalarial drugs before, during, and after travel to endemic areas).
– **Vaccination:** The development and recommended use of the RTS,S/AS01 malaria vaccine (Mosquirix) and R21/Matrix-M for children in high-transmission areas represents a major new tool in the fight against the disease.
Understanding the intricate molecular and biological processes of the Plasmodium life cycle, coupled with effective public health measures like prompt diagnosis and vector control, remains central to any strategy aimed at eliminating malaria.